1. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study.
- Author
-
Bovenzi R, Conti M, Pierantozzi M, Testone G, Fernandes M, Manfredi N, Schirinzi T, Cerroni R, Mercuri NB, Stefani A, and Liguori C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Monoamine Oxidase Inhibitors pharmacology, Monoamine Oxidase Inhibitors administration & dosage, Antiparkinson Agents administration & dosage, Antiparkinson Agents pharmacology, Sleep drug effects, Sleep physiology, Parkinson Disease drug therapy, Parkinson Disease physiopathology, Parkinson Disease complications, Alanine analogs & derivatives, Alanine pharmacology, Alanine administration & dosage, Polysomnography, Sleep Wake Disorders drug therapy, Sleep Wake Disorders etiology, Indans pharmacology, Indans administration & dosage, Benzylamines pharmacology, Benzylamines administration & dosage
- Abstract
Introduction: Sleep problems commonly occur in Parkinson's disease (PD) and significantly affect patients' quality of life. A possible effect on subjective sleep disturbances of monoamine oxidase-B inhibitors (MAOB-Is) has been described., Methods: This prospective, observational, single-centre study involved 45 fluctuating PD patients complaining sleep problems as documented by the PD Sleep Scale -2nd version (PDSS-2 ≥18) starting rasagiline 1 mg/daily or safinamide 100 mg/daily, according to common clinical practice, and maintaining antiparkinsonian therapy unchanged. Polysomnography (PSG), sleep questionnaires (PDSS-2, Epworth Sleepiness Scale - ESS), and motor function were evaluated at baseline (T0) and after 4 months of treatment (T1)., Results: Safinamide was prescribed in thirty patients and rasagiline in fifteen patients. Both drugs induced a significant improvement in Movement Disorder Society Unified PD Rating Scale III scores. Patients treated with rasagiline showed a significant increase in stage 1 (N1) Non-REM sleep compared to T0, with no significant effects on sleep scales. Patients treated with safinamide showed a significant increase in stage 3 of Non-REM sleep and sleep efficiency and a reduction in the rate of periodic limb movements, matching a significant reduction in PDSS-2 and ESS scales compared to T0., Conclusion: This study showed that safinamide, in addition to having a significant effect on PD motor symptoms, like the other MAOB-Is, may exert a specific beneficial effect on subjective and objective sleep, probably driven by its dual mechanism of action, which involves both dopaminergic and glutamatergic neurotransmission., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF